ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study
New Clinical Advisory Board Established to Provide Industry Leadership and Ophthalmology Experience
26-Feb-2009 -
ESBATech AG announced the initiation of a Phase IIa study in patients with acute anterior uveitis. This study is designed to evaluate the safety, tolerability, and clinical activity of topically applied ESBA105 in uveitis patients. ESBA105 is a single-chain antibody fragment directed against ...
acute anterior uveitis
antibody fragments
diseases
+5